Title and Organization:
Ted W. Love, M.D. became Chief Executive Officer of Global Blood Therapeutics in June of 2014. He served as Executive Vice President and Head of Research and Development for Onyx Pharmaceuticals from January 2010 until 2014. In January 2011 he assumed responsibility for technical operations. Prior to joining Onyx, Ted was President, Chief Executive Officer and Chairman of the Board of Directors at the Nuvelo, which he joined in 2001. Ted joined Nuvelo from Theravance Inc., where he served as Senior Vice President of Development from February 1998 to January 2001. Earlier in his career; Ted spent six years at Genentech, Inc. where he held a number of senior management positions in Medical Affairs and Product Development. As Vice President of Product Development and Regulatory Affairs at Genentech, he oversaw all drugs in development including Herceptin, Rituxan, and TNKase. He also served as Chairman of Genentech's Product Development Committee. Ted earned his B.A. in molecular biology from Haverford College and his M.D. at Yale Medical School. He completed his residency and fellowship training in internal medicine and cardiology at Harvard Medical School and Massachusetts General Hospital, where he later served on the faculty in the department of cardiology. Ted currently serves on the Board of Directors of Amicus Therapeutics and Global Blood Therapeutics. He previously served on the boards of Bio-Rad Laboratories, Inc., Predix Pharmaceuticals, Inc., Santarus, Inc., Affymax, Inc., ARCA biopharma, Inc., and on the California Institute for Regenerative Medicine (CIRM) Independent Citizens' Oversight Committee), which manages the 3 billion dollars allocated to stem cell research authorized by Proposition 71. He is a member of the 2002 Class of Henry Crown Fellows and the Aspen Global Leadership Network at the Aspen Institute.